Bioventus Inc
NASDAQ:BVS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Zhejiang Semir Garment Co Ltd
SZSE:002563
|
CN |
|
Hangzhou Kelin Electric Co Ltd
SSE:688611
|
CN |
|
TPV Technology Co Ltd
SZSE:000727
|
CN |
|
B
|
BeiJing Seeyon Internet Software Corp
SSE:688369
|
CN |
|
M
|
Mayer Holdings Ltd
HKEX:1116
|
HK |
|
Ground Rents Income Fund PLC
LSE:GRIO
|
UK |
|
Bounty Oil and Gas NL
ASX:BUY
|
AU |
|
D
|
Danlaw Technologies India Ltd
BSE:532329
|
IN |
|
Texas Roadhouse Inc
NASDAQ:TXRH
|
US |
Bioventus Inc
Other Current Assets
Bioventus Inc
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bioventus Inc
NASDAQ:BVS
|
Other Current Assets
$10.9m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Haemonetics Corp
NYSE:HAE
|
Other Current Assets
$63.4m
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
4%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Other Current Assets
$86.2m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
22%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Other Current Assets
$137.7m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
47%
|
CAGR 10-Years
18%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Other Current Assets
$102.1m
|
CAGR 3-Years
98%
|
CAGR 5-Years
47%
|
CAGR 10-Years
28%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Other Current Assets
$36.4m
|
CAGR 3-Years
12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
9%
|
|
Bioventus Inc
Glance View
Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 1,200 full-time employees. The company went IPO on 2021-02-11. The firm is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.
See Also
What is Bioventus Inc's Other Current Assets?
Other Current Assets
10.9m
USD
Based on the financial report for Dec 31, 2025, Bioventus Inc's Other Current Assets amounts to 10.9m USD.
What is Bioventus Inc's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
8%
Over the last year, the Other Current Assets growth was -23%. The average annual Other Current Assets growth rates for Bioventus Inc have been -16% over the past three years , 8% over the past five years .
